MULTIPLE MYELOMA

<em>Targeted Oncology</em>&trade; will launch its third &ldquo;Expert Perspective: Virtual Tumor Board&rdquo; on Monday, September 24.&nbsp;Each Virtual Tumor Board is a video-editorial discussion that features key opinion leaders from a specific oncological field considering options for treating patients based on case scenarios. This episode will focus on multiple myeloma.

The combination of selinexor and dexamethasone induced an overall response rate of 26.2% and a median overall survival of 8.6 months in patients with penta-refractory multiple myeloma, according to phase IIb results presented at the 2018 SOHO Annual Meeting.

Consistent benefit was seen with carfilzomib (Kyprolis)-based regimens across subgroups of patients with multiple myeloma in the ASPIRE and ENDEAVOR trials, according to updated safety data reported at the 2018 SOHO Annual Meeting.

Treatment of Multiple Myeloma with High-Risk Cytogenetics

Deepu Madduri, MD, assistant professor at Mount Sinai Hospital, discusses the biggest challenge oncologists currently face since the introduction of novel agents to the field of multiple myeloma.&nbsp;